Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.59 |
| ▸ | CTSB | P07858 | 1/20 | 0.59 |
| ▸ | CTSS | P25774 | 1/20 | 0.59 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.58 |
| ▸ | PREP | P48147 | 3/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13374867 | 0.96 | PREP (0.61) | CTSKPREPNPSR1TSHRL3MBTL1 | |
| SCHEMBL3560163 | 0.96 | PREP (0.61) | CTSKPREPNPSR1TSHRL3MBTL1 | |
| SCHEMBL8415456 | 0.88 | TSHR (0.61) | CTSKCTSBCTSSFKBP1APREP | |
| SCHEMBL14665154 | 0.88 | TSHR (0.61) | CTSKCTSBCTSSFKBP1APREP | |
| SCHEMBL13500680 | 0.88 | PREP (0.61) | CTSKCTSBCTSSFKBP1APREP | |
| SCHEMBL13119286 | 0.88 | PREP (0.61) | CTSKCTSBCTSSFKBP1APREP | |
| SCHEMBL14828710 | 0.88 | PREP (0.61) | CTSKCTSBCTSSFKBP1APREP | |
| SCHEMBL12953075 | 0.87 | TSHR (0.58) | CTSKCTSBCTSSFKBP1APREP | |
| SCHEMBL3691433 | 0.86 | PREP (0.63) | FKBP1APREPNPSR1TSHRL3MBTL1 | |
| SCHEMBL3578099 | 0.85 | FKBP1A (0.71) | CTSKCTSBCTSSFKBP1APREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1723121-B1 | 1,4-DIARYL-DIHYDROPYRIMIDIN-2-ONES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | Bayer Pharma AG (DE) | 2012-07-25 | — | — | EP | disclosed |
| EP-1723121-B1 | 1,4-DIARYL-DIHYDROPYRIMIDIN-2-ONES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | Bayer Pharma AG (DE) | 2012-07-25 | — | — | EP | disclosed |
| US-8101615-B2 | Chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction, heart failure | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-24 | — | — | US | disclosed |
| US-8101615-B2 | Chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction, heart failure | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-24 | — | — | US | disclosed |
| US-8101615-B2 | Chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction, heart failure | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-24 | — | — | US | disclosed |
| US-20080064704-A1 | 1,4-Diaryl-Dihydropyrimidin-2-Ones and Their Use as Human Neutrophil Elastase Inhibitors | BAYER HEALTHCARE AG (DE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064704-A1 | 1,4-Diaryl-Dihydropyrimidin-2-Ones and Their Use as Human Neutrophil Elastase Inhibitors | BAYER HEALTHCARE AG (DE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064704-A1 | 1,4-Diaryl-Dihydropyrimidin-2-Ones and Their Use as Human Neutrophil Elastase Inhibitors | BAYER HEALTHCARE AG (DE) | 2008-03-13 | — | — | US | disclosed |
| WO-2005082864-A1 | 1,4-DIARYL-DIHYDROPYRIMIDIN-2-ONES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064704-A1 | 1,4-Diaryl-Dihydropyrimidin-2-Ones and Their Use as Human Neutrophil Elastase Inhibitors | SERPINB1, ELANE, MPO | CTSK 93/4885CTSB 82/4885CTSS 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.